|
| Press Releases |
|
 |
|
| Monday, August 11, 2025 |
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products |
| Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. more info >> |
|
|
康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162% |
| 專注於微創介入冷凍治療領域的創新醫療器械公司康灃生物科技（上海）股份有限公司（「康灃生物」或「公司」，股份代號：6922.HK）公布其截至2025年6月30日止六個月的中期業績。 more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024 |
| Cryofocus Medtech (Shanghai) Co., Ltd. ('Cryofocus Medtech' or the 'Company', stock code: 6922.HK), announced its annual results for the year ended 31 December 2024 (the 'Reporting Period'). more info >> |
|
|
康沣生物2024年收入及毛利稳步增加 持续坚定研发投入 |
| 专注于微创介入冷冻治疗领域的中国创新医疗器械公司康沣生物科技(上海)股份有限公司(“康沣生物”或“公司”，股份代号；6922.HK)，公布其截至2024年12月31日止年度(“报告期”)业绩。 more info >> |
|
|
康灃生物2024年收入及毛利穩步增加 持續堅定研發投入 |
| 專注於微創介入冷凍治療領域的中國創新醫療器械公司康灃生物科技(上海)股份有限公司(「康灃生物」或「公司」，股份代號；6922.HK)，公佈其截至2024年12月31日止年度(「報告期」)業績。2024年，康灃生物實現總營收5,350萬元(人民幣，下同)，同比增長30.7%，主要受心臟冷凍消融系統、冷凍黏連治療系統及其他呼吸介入產品的銷量增加所帶動。報告期內，毛利同比增加23.7%至達3,840萬元，毛利率約71.8%。 more info >> |
|
| Tuesday, December 12, 2023 |
|
|
康沣生物心脏冷冻消融系统获NMPA批准上市 |
| 专注于微创介入冷冻治疗领域的中国创新医疗器械公司——康沣生物科技（上海）股份有限公司（以下简称「公司」或「康沣生物」，6922.HK）发布自愿性公告，公司自主开发的心脏冷冻消融系统已获中国国家药品监督管理局（NMPA）批准上市。 more info >> |
|
|
康灃生物心臟冷凍消融系統獲NMPA批准上市 |
| 專注於微創介入冷凍治療領域的中國創新醫療器械公司——康灃生物科技（上海）股份有限公司（以下簡稱「公司」或「康灃生物」，6922.HK）發佈自願性公告，公司自主開發的心臟冷凍消融系統已獲中國國家藥品監督管理局（NMPA）批准上市。 more info >> |
|
|
Cryofocus Medtech Obtains NMPA Approval for the AF Cryoablation System |
| The innovative medical device company in China with a main focus on the field of minimally-invasive interventional cryotherapy more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Icarus' Future: A Miami-Born Campaign Telling COP30 Leaders Our Children's Future is at Stake - Just Won Seven LUUM Awards
Nov 18, 2025 08:00 HKT/SGT
|
|
|
Radisson Announces Exercise of Warrants
Nov 18, 2025 06:29 HKT/SGT
|
|
|
Mazda Begins Demonstration Experiment of Onboard CO2 Capture System
Nov 17, 2025 0:38 JST
|
|
|
Pushing Hydrogen Engine Technology to New Heights in the Super Taikyu Series Final Race
Nov 17, 2025 0:00 JST
|
|
|
Graid Technology 完成與英特爾 VROC 的授權協議，拓展其在企業儲存解決方案領域的領導地位
Nov 17, 2025 23:00 HKT/SGT
|
|
|
OBI-902、米国FDAより胆管癌治療を対象とした希少疾病用医薬品指定を取得
Nov 17, 2025 23:00: JST
|
|
|
Fujitsu launches business creation lab in collaboration with AWS Japan
Nov 17, 2025 23:41 JST
|
|
|
NTT DOCOMO Achieves Successful Outdoor Trial of AI-Driven Wireless Interface Toward 6G
Nov 17, 2025 23:05 JST
|
|
|
Graid Technology Finalizes Intel VROC Licensing Agreement, Expanding Leadership in Enterprise Storage Solutions
Nov 17, 2025 22:00 HKT/SGT
|
|
|
JBM Healthcare Announces FY2026 Interim Results
Nov 17, 2025 21:43 HKT/SGT
|
|
|
健倍苗苗公佈二零二六財政年度中期業績
Nov 17, 2025 21:43 HKT/SGT
|
|
|
健倍苗苗公布二零二六财政年度中期业绩
Nov 17, 2025 21:43 HKT/SGT
|
|
|
Destinator Earns the Highest Rating of Five Stars in 2025 ASEAN NCAP
Nov 17, 2025 22:32 JST
|
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Nov 17, 2025 22:08 JST
|
|
|
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 21:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
